• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Exendin 3 (9-39)

Exendin 3 (9-39)

Product ID E9418
Cas No. 133514-43-9
Purity ≥95%
Product Unit SizeCostQuantityStock
0.5 mg $147.00 In stock
1 mg $236.30 In stock
2.5 mg $472.50 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Exendin 3 (9-39) is a gastrointestinal motility modulating peptide fragment of exendin-3. This peptide acts as an antagonist at glucagon-like peptide 1 (GLP-1) receptors, increasing spontaneous contractions in colon circular muscle. This peptide inhibits the effects of exendin-4 and other GLP-1 agonists. Exendin-3 was originally found in Heloderma lizards.

Product Info

Cas No.

133514-43-9

Purity

≥95%

Formula

C149H234N40O47S

Formula Wt.

3369.83

Synonym

9-39-Exendin 3(Heloderma horridum) (9CI), Exendin 3 (9-39)

Solubility

Soluble in water (1 mg/mL), DMSO.

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

E9418 MSDS PDF

Info Sheet

E9418 Info Sheet PDF

References

Amato A, Baldassano S, Liotta R, et al. Exogenous glucagon-like peptide-1 reduces contractions in human colon circular muscle. J Endocrinol. 2014 Jan 17. [Epub ahead of print]. PMID: 24443715.

Hu G, Zhang Y, Jiang H, et al. Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression. Cardiol J. 2013;20(6):600-4. PMID: 24338536.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R1626

    Regorafenib Monohydrate

    VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B...

    ≥99%
  • A4940

    6-Aminonicotinamide

    G6PDH inhibitor.

    ≥98%
  • G0152

    Ganciclovir

    Nucleoside (guanosine) analog; DNA chain termin...

    ≥98%
  • G0000

    G250.A2 Peptide

    Peptide, carbonic anhydrase G250 epitope.

    ≥95%
  • E7858

    Etoricoxib

    NSAID; COX-2 inhibitor.

    ≥99%
  • C0048

    Cambinol

    SIRT inhibitor.

    ≥98%
  • D5792

    Doxofylline

    Xanthine derivative; PDE inhibitor.

    ≥98%
  • C4517

    Clenbuterol Hydrochloride

    β2-adrenergic agonist.

    ≥98%
  • A464766

    Altenuene

    Alternaria mycotoxin which may be found in food...

    ≥98%
  • A985132

    AZD-8186

    Selective inhibitor of PI3Kβ and PI3Kδ.

    ≥99%
  • C2540

    CGK 733

    ATM and ATR inhibitor.

    ≥98%
  • F1652

    Fenbufen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • R3221

    3-Formylrifamycin

    Rifamycin derivative, induces pore formation in...

    ≥98%
  • B3374

    Bisacodyl

    Diphenylmethane derivative, stimulates colonic ...

    ≥98%
  • L9602

    LY-2874455

    FGFR inhibitor.

    ≥98%
  • M1685

    Mevastatin

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • L0360

    Lapatinib Ditosylate Monohydrate

    EGFR inhibitor.

    ≥99%
  • P9869

    Pyridoxine Hydrochloride

    Vitamin B6 derivative, antioxidant.

    ≥98%
  • N3301

    Niacin

    Vitamin B, required for formation of NAD and NA...

    ≥98%
  • D1869

    Deracoxib

    NSAID; COX-2 inhibitor.

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only